The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.
H. Mackay
No relevant relationships to disclose
S. Welch
No relevant relationships to disclose
M. S. Tsao
No relevant relationships to disclose
J. J. Biagi
No relevant relationships to disclose
L. Elit
No relevant relationships to disclose
P. Ghatage
No relevant relationships to disclose
L. A. Martin
No relevant relationships to disclose
K. S. Tonkin
No relevant relationships to disclose
S. Ellard
No relevant relationships to disclose
S. K. Lau
No relevant relationships to disclose
L. McIntosh
No relevant relationships to disclose
E. A. Eisenhauer
No relevant relationships to disclose
A. M. Oza
No relevant relationships to disclose